First in Human - Molecure

RB nr 8 Zawarcie umowy na zorganizowanie i kompleksowe przeprowadzenie badania klinicznego pierwszej fazy typu ‘First in Human’ dla związku OATD-02

RB nr 27 Informacja nt. wyboru wykonawcy w celu zorganizowania i kompleksowego przeprowadzenia badania klinicznego pierwszej fazy typu ‘First in Human’ dla związku OATD-02

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer

OATD-02 is an oral, potent and selective dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer Phase I clinical trial to assess safety, tolerability and preliminary efficacy of OATD-02 in patients with advanced and/or

OncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients

OncoArendi Therapeutics - a clinical stage biotechnology company specializing in the discovery and development of innovative small molecule drugs continues the clinical development of its first-in-class experimental drug candidate for treatment of sarcoidosis and idiopathic pulmonary

OncoArendi Therapeutics Announces Selection of Its Second Clinical Development Candidate: OATD-02 For the Treatment of Multiple Cancers

Warsaw, Poland, June 21, 2017 / B3C newswire / -- During the first Company Presentation at the global BIO Conference in San Diego OncoArendi Therapeutics SA announced that it has selected OATD‑02 as its clinical development candidate

Molecure has published its financial report for 2023 – the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

Molecure can proceed with clinical trials in the U.S.A – Phase II proof-of-concept study will be the first to treat patients suffering from pulmonary sarcoidosis with OATD-01 In the coming weeks Molecure will also seek the

Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.

The agreement with Simbec-Orion includes organizing and fully executing a proof-of-concept Phase II clinical trial in patients with pulmonary sarcoidosis. The Phase II proof-of-concept study of OATD-01 will be conducted as multi-center and international clinical trial

Search Results for: First in Human

RB nr 8 Zawarcie umowy na zorganizowanie i kompleksowe przeprowadzenie badania klinicznego pierwszej fazy typu ‘First in Human’ dla związku OATD-02

RB nr 27 Informacja nt. wyboru wykonawcy w celu zorganizowania i kompleksowego przeprowadzenia badania klinicznego pierwszej fazy typu ‘First in Human’ dla związku OATD-02

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer

OncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients

OncoArendi Therapeutics Announces Selection of Its Second Clinical Development Candidate: OATD-02 For the Treatment of Multiple Cancers

Molecure has published its financial report for 2023 – the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.